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Abstract: The emergence of antimicrobial resistance is causing the loss of what was once considered
the miracle cure. The transmission of antimicrobial resistance during mass gathering is a potential
threat in addition to other infectious diseases. Here, we review the English language literature
on the rate and the acquisition of antimicrobial resistance during the Hajj. There is a variable
incidence of methicillin-resistant Staphylococcus aureus, Escherichia coli, and Enterobacteriaceae. There
had been no report of multi-drug-resistant Mycobacterium tuberculosis. Continued surveillance of
antimicrobial resistance coupled with public health measures are needed to decrease the rate of
emergence of resistance.
Keywords: Hajj; mass gathering; antimicrobial resistance
1. Introduction
It is known that there is an increasing trend in antimicrobial resistance among Gram-
negative and Gram-positive bacteria. In a systematic review, the prevalence of findings,
the prevalence of vancomycin-resistant Enterococcus faecium is high in the Eastern Mediter-
ranean countries [1]. Another study showed increasing antimicrobial resistance among
Acinetobacter baumannii globally as well [2]. The issue of antimicrobial resistance might be
even exaggerated in the setting of mass gatherings such as the annual Hajj. There is also an
increase in antimicrobial-resistant bacteria in the Kingdom of Saudi Arabia [3].
The annual Muslim Pilgrimage, Hajj, and the mini-Hajj, Umrah, are recurrent mass
gathering events that take place annually in Makkah, Kingdom of Saudi Arabia (KSA).
The annual Hajj is one of the largest recurrent mass gatherings (MGs) and accommodates
two to three million Muslims who come from > 180 countries around the world [4,5]. This
annual Hajj is considered one of five pillars of Islam and is a mandatory to be performed
by able and capable adult Muslims once in a lifetime. However, Umrah is a shorter version
of the Hajj and can be done optionally at any time during the year, whereas the Hajj has to
be done in a specified period time in relation to the Lunar, Islamic, Calendar [5–7]. The
estimated annual pilgrimage for both Hajj and Umrah is more than 10 million pilgrims [8].
The number of the annual Hajj pilgrims per year has increased from 1996 till 2012 when the
grand mosque expansion project was started (Figure 1). The number of pilgrims decreased
significantly during the COVID-19 pandemic.
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The occurrence of diarrheal illnesses among attendees of mass gatherings is well estab-
lished and continues to be included in the surveillance program during the Hajj [9,12,20–22].
The reported rates of diarrhea among pilgrims range from 1.1% to 23.3% in multiple cohort
studies of 262,999 pilgrims from 2002 to 2013 [20].
Diarrheal illness among Hajj pilgrimage is another area of concern as it might be
caused by antimicrobial-resistant organisms with the potential to spread during the mass
gathering event. In one study, the most frequently associated pathogens in patients with
diarrhea during the Hajj were: Salmonella spp., Shigella, enteroinvasive Escherichia coli
(EIEC) and enterotoxigenic Escherichia coli (ETEC) [23]. In a systematic review of 15 studies
of 262,999 pilgrims from 2002 to 2013 showed that the prevalence of diarrheal illness
among pilgrimage was 2.3% (range: 1.1–23.3%) [21]. Cited risk factors for diarrhea among
pilgrimage were: eating in restaurants [24] and being male [25,26], however, the source
of food and eating raw vegetables were not associated significantly with the occurrence
of diarrhea [25]. Diarrheal illness was reported among 12% of attendees in the annual
Arbaeen mass gatherings in Iraq [27] and among 4.5% among attendees of the 2015 Grand
Magal [28] in one study, and 14.5% had gastrointestinal symptoms in another study [29].
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2. Antimicrobial-Resistant Bacteria among Diarrheal Pathogens
In one study, 40% of Salmonella and E. coli-diarrheal pathogens were extended-spectrum
β-lactamases (ESBLs) and carbapenemases such as blaCTX-M-15 and blaNDM elements [23].
This high rate is alarming giving the fact that the Hajj pilgrimage attracts > 2 million
pilgrims from 188 countries [22]. In another study, 2 of 267 rectal swabs were posi-
tive for Salmonella Newport serotype and these were resistant to multiple antibiotics
(cephalosporins, gentamicin and colistin) and had bla(CTX-M-2) gene and had colistin
resistance [30].
3. Antimicrobial-Resistant Bacteria among Enterobacteriaceae
Resistance to third generation cephalosporins was reported among 19–94% of E. coli
and K. [31–34]. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae
was found among pilgrims and multiple isolates had CTX-M type ESBL genes [30,35].
Another study of urinary E. coli isolates in pilgrims showed the presence of E. coli ST131
and ST648 [36]. One study of French pilgrims showed one E. coli isolate with blaNDM-5,
blaCTX-M-15, blaTEM-1, and aadA2 (ST2659 and ST181) genes [37]. The presence of the
mcr-1 plasmid mediating colistin resistance was found at a rate of 9% [38]. ESBL genes,
blaCTX-M, blaTEM, and blaSHV, were reported in two studies conducted in ICU patients.
The proportion of blaCTX-M and blaTEM in E. coli and K. pneumoniae cases was 18.5–30%,
blaSHV was 7.4% and 17.2% among E. coli and K. pneumoniae, respectively [39,40]. The
rate of imipenem-resistance among E. coli and K. pneumoniae was 4–11.9% [31,34,41]. For
carbapenem-resistant P. aeruginosa isolated from patients, 4.1–18.4% carried blaVIM and
4.7–21.0% carried blaIMP [39,42,43]. Shiga toxin-producing E. coli among diarrheal isolates
showed 70% resistance to trimethoprim-sulfamethoxazole [44]. A number of studies
showed different extended-spectrum-β-lactamase (bla) genes that had been identified in
the Hajj [23,35–37,45,46] (Table 1).
Table 1. A Summary of the different extended-spectrum-β-lactamase (bla) genes that had been
identified in the Hajj.
Gene Organism Reference
blaCTX-M-15 Salmonella spp. and E. coli [23,36,37]
blaOXA-72 Acinetobacter baumannii [37]
blaNDM-5 Escherichia coli [37]
blaCTX-M Escherichia coli, K. pneumoniae [35–37,45]
blaNDM Salmonella, enterotoxigenic E. coli,K. pneumoniae, [23,37,46]
blaOXA E. coli, K. pneumoniae,Acinetobacter baumannii [36,37,46]
blaTEM E. coli, K. pneumoniae, [35–37]
blaSHV E. coli, K. pneumoniae, [35,36]
blaVIM K. pneumoniae [46]
aac6, aac6Ib, aadA4, strB, aadA1,
aadA2, aadB, ant2, aphA, strA aminoglycoside-resistant E. coli [36]
4. Antimicrobial Resistance among Acinetobacter baumannii and P. aeruginosa
The rate of imipenem-resistance among A. baumannii and P. aeruginosa was 4–60.5%
and 4–43%, respectively. The prevalence of blaOXA-23 was 91% among A. baumannii
causing infection in ICU patients [39]. The occurrence of metallo-β-lactamase genes
among carbapenem-resistant A. baumannii isolates was 11.5–27.1% for blaVIM and 13.6% for
blaIMP. [39,42,43]. In a study of French pilgrims, the rate of isolation of ceftriaxone-resistant
A. baumannii with blaOXA-51-like gene was 14.4% throat, 25.6% rectal, and 3.3% from throat
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and rectal swabs [37]. The study was showed one A. baumannii isolate with imipenem
resistance and had blaOXA-72 carbapenemase gene [37].
5. Occurrence of Methicillin-Resistant Staphylococcus aureus (MRSA) and
Vancomycin-Resistant S. aureus (VRSA)
The incidence of methicillin-resistant Staphylococcus aureus (MRSA) in isolates from
patients during the Hajj had steadily increased overtime in parallel with the incidence in
the community and the healthcare settings [47]. MRSA incidence was 2–7% in pilgrims in
2000–2004 [48], 28% in patients with sinusitis in 2014 [49] and 63% in community acquired
infections in 2015 [50]. The rate of MRSA was 15–20% in Hajj pilgrimages and 10–11% in
Umrah pilgrims and the rate was similar before and after participating in the events [51].
The incidence of MRSA among food handlers in Makkah was 0% in 2001–2002 and was
20% in 2014 [52,53]. Occurrence of vancomycin-resistant S. aureus (VRSA) was 2% among
pilgrims [54]. The specific resistance gene was investigated among S. aureus isolates and these
studies showed the presence of Panton-Valentine leucocidin (PVL) in 0–19% [55,56]. The
presence of the fibronectin binding protein (fnBPA)-encoding gene in MRSA was 8% [55]. A
summary of studies examining the occurrence of Methicillin-Resistant Staphylococcus aureus
in the Hajj pilgrims and workers is shown in Table 2 [33,41,48–58].
Table 2. A summary of Studies Examining Methicillin-Resistant Staphylococcus aureus in the Hajj pilgrims and workers.
Study Year Source Number of Individuals with MRSA/No. ofIndividuals with Positive Culture (%) Reference
2000–2001 Skin lesion 1/47 (2.1) [48]
2000–2001 Multiple sites 0/45 (0) [52]
2004 Nasal, axilla, groin and open wound swabs 6/85 (7.1) [57]
2009 Nasal swabs 16/155 (10.3) [51]
2009 Nasal swabs 30/153 (19.6) [51]
2014 Nasal and hand skin swabs 33/165 (20.0) [53]
2014 Sinus 13/46 (28.3) [49]
2015 Urine, blood, sputum 36/57 (63.2) [50]
2003–2004 Wound swabs, ear swabs, eye swabs, blood,urine, respiratory tract 199/512 (38.9) [58]
2004–2005 Blood 161/303 (53.0) [41]
2008–2009 Multiple 271/688 (39.4) [54]
2011–2012 Foot infection and urinary tractinfection samples 15/26 (57.7) [33]
2012 No data 100/206 (48.5) mec19/100 (19.0) PVL [56]
No data Blood cultures, wound swabs, urine,nasal swabs, and sputum 11/50 (22.0) [55]
6. Resistance among Other Gram-Positive Organisms
Resistance to vancomycin among Enterococcus faecalis was 3.5% and 2% for Entero-
cocci [54]. Oxacillin-resistant coagulase-negative staphylococci (CoNS) rate was 61% in
2004–2005, 82.4% in 2008–2009, and 93.6% in 2012–2013 [41,54,59].
7. Occurrence of Antibiotic-Resistant Respiratory Bacterial Pathogens
among Pilgrimages
In a study of the carriage of Streptococcus pneumoniae among pilgrims showed that
23% of such isolates were resistant to multiple antibiotics (≥3 classes of antibiotics) [60]
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with a rate of 21% for ampicillin-resistant S. pneumoniae [54]. In the same cohort study
among 110 isolates from pilgrims, S. pneumoniae resistance was as follows: 30.9% were
penicillin non-susceptible, 2.7% were intermediately resistant to amoxicillin and 1.8%
were intermediately resistant to cefotaxime, 24.5% were resistant to erythromycin, 12.7%
were resistant to clindamycin, 55.5% were resistant to tetracycline, 6.4% were resistant to
chloramphenicol, 48.2% were resistant to trimethoprim-sulfamethoxazole, and 16.4% were
intermediately resistant to trimethoprim-sulfamethoxazole [60].
8. Tuberculosis and the Hajj
Due to the crowding conditions and the fact that 50% of pilgrims arrive from places
with high prevalence of tuberculosis, including Africa, Bangladesh, India, Pakistan and
Southeast Asia [61]. The occurrence of pulmonary tuberculosis had been described among
pilgrims. However, the data regarding drug resistance are sparse. The prevalence of active
pulmonary tuberculosis is variable (1.2–10%) among hospitalized patients [61–65] (Table 3).
One study of 1063 pilgrims showed that 15 (1.4%) had pulmonary tuberculosis and there
was no multidrug-resistant cases [66]. However, there had been no description of any
outbreak of tuberculosis related to the Hajj.
Table 3. A summary of studies describing active tuberculosis among Pilgrims.
Number of Admitted Pilgrims Number (%) with Active Tuberculosis Reference
30 3 (10) [62]
46 9 (20) [63]
808 10 (1.2) [64]
452 22 (4.9) [61]
118 1 (1) [65]
1063 15 (1.4) [66]
9. Transmission of Meningococcal Disease
Neisseria meningitidis is one of the most studied organisms when it comes to the Hajj and
pilgrimage and it was associated with multiple outbreaks [11,67–73]. There had been two
major outbreaks of N. meningitides in relation to the 1987 Hajj and the 2000–2001 [11,67–69].
Asymptomatic N. meningitidis was >80% and had a significant impact on the Hajj outbreaks
during Hajj in 1987 and 2000–2001 [69,74]. In a recent study of 628 paired cohort pilgrims,
the rate of acquisition of N. meningitidis was 5.7% on arrival and 2.5% on departure [68].
The outbreak in 1987 was caused by N. meningitidis serogroup A [74–76], and serogroup
W135 [77]. The outbreaks in 2000–2001 were also associated with resistance to trimethoprim-
sulfamethoxazole, sulfadiazine, cloxacillin and tetracycline [78]. Following the first out-
break the bivalent A and B meningococcal vaccine became mandatory and the quadriva-
lent (ACYW135) vaccine became mandatory after the second outbreak. The occurrence of
azithromycin resistance among pilgrims was 8.3% and 10.3% before and after Hajj pilgrimage
and 5% for ciprofloxacin [51]. Another study showed resistance among N. meningitides was as
follows 5% to ciprofloxacin, 12% to ceftriaxone, 3% to rifampicin, and 9% to azithromycin [79].
10. Other Resistant Pathogens
The prevalence of resistance among Helicobacter pylori was 31% for metronidazole and
3% for tetracycline and erythromycin [80].
11. Discussion
It had been shown that mass gatherings such as the Hajj are significant pools for the
spread and transmission of antimicrobial-resistant bacteria due to crowded conditions,
droplet transmission, and lack of efficient personal hygiene [21]. There had been an
increased rates of AMR in the Hajj pilgrims. The occurrence of plasmid-mediated resistance
among bacteria may suggest that these bacteria may be transmitted across different pilgrims.
It was shown that the spread of clones and specific AMR genes are associated with travel
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and food [81]. The detection of these AMR in pilgrims may provide an area for further
research and investigation of ways of transmissions especially that the Hajj time changes
overtime and falls in the summer season every 10 years [82].
Meningococcal disease continues to be a potential public risk at the Hajj due to
the invasiveness of the disease, increasing antimicrobial resistance, diverse serotypes (A,
C, W-135, Y, and others), changes in the incidence, and alterations in serogroups and
genotypes [83]. Colonization by N. meningitidis can be a major potential source of infection
and is a potential source of the spread to other parts of the world [9,60,84,85]. There had
been several studies examining the rate of N. meningitidis and the rate was variable from
0% to 6.3% [86–88]. One study of a paired cohort showed a prevalence of N. meningitidis
of 2.5% on arrival and 1.3% on departure [87,88]. Another paired cohort study showed a
prevalence of 2.5% on arrival and 0.15% upon departure to have N. meningitidis [68]. A
third cohort study showed rates of 0.3% and 0.6% of N. meningitides among paired cohort
and non-paired cohort, respectively [89]. Another cohort French study showed 0% of
N. meningitides on arrival and departure [90]. Ciprofloxacin prophylaxis had shown to
decrease N. meningitidis carriage as follows: no ciprofloxacin group had 5.2% before and
4.6% after pilgrimage (P = 0.65) and with ciprofloxacin the rate was 8.1% and 0% before and
after pilgrimage [91]. Mandatory ciprofloxacin prophylaxis is given to pilgrims arriving
from Sub-Saharan African meningitis belt countries [10,74,92–94].
Use of antimicrobial agents without a prescription is a major drive to the development
of antibiotic resistance and this is true in the case of the Hajj [95] and one study showed
that 47.6% of pilgrims used antibiotics [96].
The main modes of transmission of antimicrobial-resistant bacteria are respiratory,
direct contact, and food-borne. As such it is important to maintain a high level of infection
control compliance among pilgrims and healthcare settings [97]. The profession of safe
food is also very important. In addition, there is a need for fast and reliable diagnostic tests.
The utilization of available vaccines would also contribute to the efforts to decrease trans-
mission of antimicrobial-resistant organisms especially respiratory tract infections. There
needs to be ongoing surveillance of bacterial and viral pathogens and the development of
antimicrobial resistance among pilgrims utilizing electronic surveillance systems [9,98].
One important method to decrease the risk of antimicrobial-resistant organisms is
vaccination that would decrease the risk of infection and thus the use of antimicrobial
therapy. The Saudi ministry of health annually revise the recommendations for the uti-
lization of vaccines during the Hajj [6,99]. These vaccines include the required and rec-
ommended vaccines. The rate of pneumococcal vaccination among pilgrims had been
variable [18,60,89,90,100–106] (Table 4).
Table 4. Pneumococcal vaccination rates in Hajj pilgrims.












In addition, the Saudi authorities had banned the selling of antibiotics without a
prescription. It is also important to continue the surveillance activities for the emergence
of any antimicrobial-resistant organisms during the Hajj. The Saudi ministry of health
had adopted electronic surveillance system [9]. The surveillance could be staged and may
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involve multiple methods such as syndromic and laboratory based surveillance [107]. The
World Health Organization (WHO) had adopted the 5-4-8-4 approach to reduce the risk
of antimicrobial resistance during the Hajj [108] and this could be applied to other mass
gathering events as well. This approach included the five pillars of the WHO strategy that
includes: increase awareness and surveillance, reduce infections, optimize antimicrobial
use, and the development of an economic case for maintainable investment in antimicrobial
resistance [109]. The next number, four, refers to the need to have clinicians adhere to
the four moments of antibiotic prescribing strategy. This moment includes: the presence
of bacterial infection requiring antibiotics, the need to order appropriate cultures and to
initiate the appropriate empiric antibiotics, how long should antibiotics be prescribed,
and when antibiotics could be stopped [110]. The number eight refers to the priority
pathogens: Acinetobacter spp., E. coli, K. pneumoniae, N. gonorrhoeae, Salmonella spp., Shigella
spp., S. aureus, S. pneumoniae. The last number refers to the four specimens to be collected
for culture (blood, urine, stool, urethral and cervical swabs) [108].
The risk of tuberculosis among pilgrims is of particular importance. There had been no
reported outbreaks of tuberculosis among pilgrims. However, the situation of pilgrims and
the overcrowding conditions may promote the spread of respiratory pathogens such as tu-
berculosis and viral infections such as the Middle East Respiratory Syndrome Coronavirus
(MERS-CoV) and the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
For tuberculosis, it is assuring to note that the recent global burden of tuberculosis study
estimates that there is a trend in the decline in the incidence of the disease and if such
decline continues then a few countries may meet the Sustainable Development Goal (SDG)
target to eliminate tuberculosis by 2030 [111]. The risk of the development of MERS-CoV
was a real issue. However, a systematic review in 2018 showed no evidence of MERS-CoV
among pilgrims [7]. A subsequent study of 28,197 returning pilgrims to Indonesia showed
no evidence of MERS-CoV infection as well [112]. The emergence of SARS-CoV-2 and the
subsequent development of the pandemic had attracted lots of attention towards the Hajj.
Thus, the Kingdom of Saudi Arabia had taken multiple steps to prevent the introduction of
the virus to the pilgrims. It was expected that the Hajj season in 2020 would be cancelled
due to the pandemic [113]. Actually, Saudi Arabia suspended the Umrah (mini-Hajj) and
limited the access to the 2020 Hajj [8]. With continued pandemic and decreasing cases in
Saudi Arabia, the government had taken steps to ease the strictions and developed a staged
approach to scaling up the Umrah Pilgrimage in the last few months of 2020 [114].
To control the increasing antimicrobial resistance globally, two important public
health proposals are to include education and training of the medical students during
undergraduate and post-graduate studies. For example, in one study, 81% of 1055 young
physicians indicated that antimicrobial resistance was not adequately addressed during
medical training [115]. This is further exemplified by a study of the knowledge, attitude
and practice of healthcare workers deployed during two Hajj seasons, where 85% indicated
hearing about antimicrobial resistance and 19% had heard about antimicrobial stewardship
programs [116]. In addition, it is important to include education and training of the young
physicians on the discipline of mass gathering to alert them to the medical risks and
challenges [117].
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